Vaccinia virus complement control protein increases early bacterial clearance during experimental peritonitis

Surgical Infections

Volumn 4, Issue 4, 2003, Pages 317-326

  Scott, Melanie J ^a   Burch, Phillip T ^a   Jha, Puroshottam ^a   Peyton, James C ^a   Kotwal, Girish J ^a,b   Cheadle, William G ^a  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; MYELOPEROXIDASE; RECOMBINANT PROTEIN; SODIUM CHLORIDE; VIRUS PROTEIN;

AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL PERITONITIS; BLOOD SAMPLING; CECUM; COMPLEMENT ACTIVATION; COMPLEMENT FACTOR; COMPLEMENT INHIBITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; LEUKOCYTE ACTIVATION; LEUKOCYTE DIFFERENTIAL COUNT; LEUKOCYTE FUNCTION; LIGATION; LIVER; LUNG PARENCHYMA; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOGENESIS; PERITONEUM LAVAGE; PRIORITY JOURNAL; RANK SUM TEST; STATISTICAL ANALYSIS; VACCINIA VIRUS;

EID: 1042280926     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/109629603322761373     Document Type: Article

References (37)

1. Christou NV, Barie PS, Dellinger EP, et al. Surgical Infection Society intra-abdominal infection study. Prospective evaluation of management techniques and outcome. Arch Surg 1993;128:193-198.
2. Holzheimer RG, Muhrer KH, L'Allemand N, et al. Intraabdominal infections: Classification, mortality, scoring and pathophysiology. Infection 1991;19: 447-452.
3. Wickel DJ, Cheadle WG, Mercer-Jones MA, Garrison RN. Poor outcome from peritonitis is caused by disease acuity and organ failure, not recurrent peritoneal infection. Ann Surg 1997;225:744-753.
4. Zarkadis IK, Mastellos D, Lambris JD. Phylogenetic aspects of the complement system. Dev Comp Immunol 2001;25:745-762.
5. Krem MM, Cera ED. Evolution of enzyme cascades from embryonic development to blood coagulation. Trends Biochem Sci 2002;27:67-74.
6. Prodeus AP, Zhou X, Maurer M, et al. Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature 1997;390:172-175.
7. Fischer MB, Prodeus AP, Nicholson-Weller A, et al. Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement. J Immunol 1997;159:976-982.
8. Schirmer WJ, Schirmer JM, Naff GB, Fry DE. Systemic complement activation produces hemodynamic changes characteristic of sepsis. Arch Surg 1988;123: 316-321.
9. Hack CE, Nuijens JH, Felt-Bersma RJ, et al. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 1989;86:20-26.
10. Huber-Lang M, Sarma VJ, Lu KT, et al. Role of C5a in multiorgan failure during sepsis. J Immunol 2001; 166:1193-1199.
11. Czermak BJ, Sarma V, Pierson CL, et al. Protective effects of C5a blockade in sepsis. Nat Med 1999;5: 788-792.
12. Kotwal GJ, Moss B. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 1988;335:176-178.
13. Sahu A, Isaacs SN, Soulika AM, Lambris JD. Interaction of vaccinia virus complement control protein with human complement proteins: factor 1-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. J Immunol 1998;160: 5596-5604.
14. McKenzie R, Kotwal GJ, Moss B, et al. Regulation of complement activity by vaccinia virus complement-control protein. J Infect Dis 1992;166:1245-1250.
15. Kotwal GJ, Isaacs SN, McKenzie R, et al. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 1990;250:827-830.
16. Smith SA, Mullin NP, Parkinson J, et al. Conserved surface-exposed K/R-X-K/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: A novel mechanism for evasion of host defense. J Virol 2000;74:5659-5666.
17. Anderson JB, Smith SA, van Wijk R, et al. Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activation. Transplant Immunol 2003;11:129-135.
18. Anderson JB, Smith SA, Kotwal GJ. Vaccinia virus complement control protein inhibits hyperacute xenorejection. Transplant Proc 2002;34:1083-1085.
19. Shrotri MS, Peyton JC, Cheadle WG. Mouse peritonitis model using cecal ligation and puncture. In Sande MA, Carbon C, Fantin B, et al., eds. Handbook of Animal Models of Infection. San Diego: Academic Press, 1999:173-181.
20. Suzuki K, Ota H, Sasagawa S, et al. Assay method for myeloperoxidase in human polymorphonuclear leukocytes. Anal Biochem 1983;132:345-352.
21. Shevach EM. In Coligan J, Kruisbeek A, Margulies D, eds. Current Protocols in Immunology. New York. Wiley, 1994:13.1.1-13.1.4.
22. Botha AJ, Moore FA, Moore EE, et al. Early neutrophil sequestration after injury: A pathogenic mechanism for multiple organ failure. J Trauma 1995;39:411-417.
23. Godshall CJ, Scott MJ, Peyton JC, et al. Genetic background determines susceptibility during murine septic peritonitis. J Surg Res 2002;102:45-49.
24. Ono S, Ueno C, Aosasa S, et al. Severe sepsis induces deficient interferon-gamma and interleukin-12 production, but interleukin-12 therapy improves survival in peritonitis. Am J Surg 2001;182:491-497.
25. Steinhauser ML, Hogaboam CM, Lukacs NW, et al. Multiple roles for IL-12 in a model of acute septic peritonitis. J Immunol 1999;162:5437-5443.
26. Marth T, Kelsall BL. Regulation of interleukin-12 by complement receptor 3 signaling. J Exp Med 1997; 185:1987-1995.
27. Wittmann M, Zwirner J, Larsson VA, et al. C5a suppresses the production of IL-12 by IFN-gamma-primed and lipopolysaccharide-challenged human monocytes. J Immunol 1999;162:6763-6769.
28. Wessels MR, Butko P, Ma M, et al. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci USA 1995;92:11490-11494.
29. Schirmer WJ, Schirmer JM, Naff GB, Fry DE. Complement activation in peritonitis. Association with hepatic and renal perfusion abnormalities. First place winner: Conrad Jobst Award. Am Surg 1987;53: 683-687.
30. Schirmer WJ, Schirmer JM, Naff GB, Fry DE. Visceral perfusion abnormalities following complement activation. Clues to the mediators of organ ischemia in trauma and sepsis. First place winner: Conrad Jobst Award. Am Surg 1988;54:687-692.
31. 5 in septic lung injury. Ann Surg 1985; 202:771-776.
32. Czermak BJ, Breckwoldt M, Ravage ZB, et al. Mechanisms of enhanced lung injury during sepsis. Am J Pathol 1999;154:1057-1065.
33. 4 receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J Exp Med 2000; 192:433-438.
34. Mercer-Jones MA, Shrotri MS, Heinzelmann M, et al. Regulation of early peritoneal neutrophil migration by macrophage inflammatory protein-2 and mast cells in experimental peritonitis. J Leukoc Biol 1999; 65:249-255.
35. Call DR, Nemzek JA, Ebong SJ, et al. Differential local and systemic regulation of the murine chemokines KC and MIP2. Shock 2001;15:278-284.
36. Kotwal GJ, Miller CG, Justus DE. The inflammation modulatory protein (IMP) of cowpox virus drastically diminishes the tissue damage by down-regulating cellular infiltration resulting from complement activation. Mol Cell Biochem 1998;185:39-46.
37. 3) of the complement system. J Neuroimmunol 2000;105:20-30.